Drug maker, Lupin, received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Mandideep Unit-2 facility in Madhya Pradesh.
The US drug regulator issues an EIR to a company when an inspection is satisfactorily closed. Lupin received EIR after the last inspection of its Mandideep-based facility was conducted from August 7 to August 11, 2023. Shares of the drug firm ended 1.04 percent down at ₹1,128.40 apiece on the BSE.
“Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!” Click here!
Catch all the Corporate news and Updates on Live Mint.
Download The Mint News App to get Daily Market Updates & Live Business News.
Download The Mint News App to get Daily Market Updates & Live Business News.
Updated: 31 Oct 2023, 07:49 PM IST